GENITOURINARY CANCERS

UroGen Pharma's ENVISION trial reveals promising long-term efficacy of intravesical mitomycin for treating low-grade bladder cancer, offering a non-surgical option.

The KEYNOTE-426 trial confirms pembrolizumab plus axitinib's long-term effectiveness for advanced kidney cancer, revealing insights into predictive biomarkers for treatment response.

Cabozantinib and atezolizumab improve progression-free survival in metastatic prostate cancer, offering hope for high-risk patients despite no overall survival benefit.

Home-based mitomycin treatment shows promise for bladder cancer patients, enhancing convenience and reducing healthcare burdens while maintaining safety and efficacy.

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic benefits during treatment.

A recent study reveals low rates of upper tract urothelial carcinoma in non-muscle-invasive bladder cancer, prompting a reevaluation of routine imaging practices.

Jacob E. Berchuck, MD, highlights novel findings pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to therapy.

A phase 2 trial shows promising safety results for carotuximab in treating advanced prostate cancer, offering hope for patients with limited options.

The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative drug delivery.

The PROGRxN-BCa study, led by Jethro C.C. Kwong, showcases a major advancement in predicting disease progression in non–muscle-invasive bladder cancer through artificial intelligence (AI).

Researchers explored a compelling new angle on the use of rectal spacers during prostate cancer radiotherapy, and emerging evidence suggests their benefits may extend further.

A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.

Joseph Jacob, MD, discusses the promising impact of TAR-200.

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, AI-driven urine test.

A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.

Biren Saraiya, MD, discusses how he sees findings from the phase 3 AMPLITUDE trial being incorporated into clinical practice for the treatment of metastatic castration-sensitive prostate cancer.

Innovative treatments for non–muscle-invasive bladder cancer emerge, focusing on bladder preservation and improved outcomes with novel therapies and active surveillance strategies.

Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive NMIBC with promising safety.

A study reveals significant genomic differences in metastatic prostate cancer among veterans, highlighting the need for universal genomic testing for precision medicine.

FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.

The FDA approved intravesical mitomycin in non–muscle-invasive bladder cancer as an nonsurgical alternative to transurethral resection of bladder tumors.

Combining sasanlimab with BCG significantly enhances event-free survival in high-risk non-muscle invasive bladder cancer, especially in CIS patients.